Germany-based Boehringer Ingelheim and United States-based Eli Lilly have revealed plans to expand their clinical trial program for Jardiance in chronic heart failure with EMPERIAL clinical trials, it was reported yesterday.
These trials will assess the effect of Jardiance on exercise ability and heart failure symptoms in people with chronic heart failure, independent of whether they have type two diabetes.
EMPERIAL includes two Phase III trials that will evaluate the effect of 12 weeks of treatment with Jardiance on the ability of people with heart failure to perform daily exercise. The plans for the EMPERIAL trials follow initiation of the EMPEROR trials in March 2017. While the EMPEROR result trials concentrate on long-term morbidity and mortality results in people with heart failure, the EMPERIAL functional trials will investigate possible benefits on exercise capacity and heart failure symptoms. These studies are based on data received from the landmark EMPA-REG OUTCOME trial, where the effect of Jardiance on heart failure outcomes was assessed.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes